There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdcscid/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.
Bibliographical noteFunding Information:
Research reported in this publication is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI132374 and U19AI142731 to T.D. and R21AI145396 to M.G. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2020 American Society for Microbiology. All rights reserved.
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases